Stay updated with breaking news from Programmed Death. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Overall response rate of 47% and disease control rate of 65% in first line recurrent/metastatic HNSCC patients treated with CUE-101 and KEYTRUDA® ORR of 56% in patients with low expression of...
BU dental researchers have found that taking down a protein in the tongue could help defeat oral cancer tumors.
Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on January 14, 2022, Health Canada has authorized TECENTRIQ® (atezolizumab) as - Click here if this is your press release! - Travel News | eTurboNews | eTN
An international research collaboration says it has found evidence pembrolizumab can reverse HIV latency – the ability for the virus to 'hide' inside cells of people living with HIV on antiretroviral therapy
(Reuters) - Researchers studying Merck & Co Inc's cancer drug Keytruda for HIV patients who also have cancer say the immunotherapy may help displace t...